ZSX Medical LLC
Internal suturing for OB/GYN and other surgeries
This article was originally published in Start Up
Executive Summary
Internal surgical closure following hysterectomies and C-sections is time-consuming, and it is associated with a number of costly complications, including infection and gynecologic adhesions. Reducing complications for patients and the resulting cost burden to health care systems worldwide are the goals of ZSX Medical LLC, which has developed a laparoscopic, bioabsorbable internal surgical closure system designed to be a superior alternative to standard suturing and stapling technologies used in hysterectomies, C-sections and other OB/GYN surgeries.
You may also be interested in...
Surgical Incision Closure: Start-Ups Address A Megatrend In Health Care
Medtech start-ups are working to develop next-generation incision closure devices that address the shortfalls of gold standard sutures and staples. We profile three hopefuls in this issue: EndoEvolution, ZipLine Medical and ZSX Medical.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.